BMS-605541 NEW
Price | $45 | $73 | $157 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-08 |
Product Details
Product Name: BMS-605541 | CAS No.: 639858-32-5 |
Purity: 98.07% | Supply Ability: 10g |
Release date: 2024/11/08 |
Product Introduction
Bioactivity
名稱 | BMS-605541 |
描述 | BMS-605541 is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity(Ki=49 nM). |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 36.1 mg/mL (90.0 mM) |
關鍵字 | BMS-605541 |
相關產品 | Ribociclib | Nintedanib | Regorafenib monohydrate | Sunitinib Malate | Sorafenib | Regorafenib | Sanguinarine chloride | Nintedanib esylate | Sorafenib tosylate | Lenvatinib mesylate | Pazopanib | Axitinib |
相關庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 激酶抑制劑庫 | 抑制劑庫 | 抗心血管疾病化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1KG |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-17 | |
$1.00/1g |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-28 | |
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY